Health · 1 sources covering this

STAT+: Eyepoint study results for vision treatment disappoint, but company still sees promise

Eyepoint said patients given its experimental treatment for wet AMD failed to maintain vision with less frequent injections compared to a standard treatment.

Share:X WhatsApp Reddit Facebook LinkedIn Open ↗

Coverage spectrum

0 L · 1 C · 0 R

How 1 sources are covering this

STATCenter·1h ago
STAT+: Eyepoint study results for vision treatment disappoint, but company still sees promise
Eyepoint said patients given its experimental treatment for wet AMD failed to maintain vision with less frequent injections compared to a standard treatment.
Read at STAT →

Embed this bias spectrum on your site

Paste this iframe wherever you'd like the widget to appear. Resizes responsively; no JS required.

<iframe
  src="https://statesidedaily.com/embed/cluster/53f578c7306041364fc928c432d704a63af65eb2"
  width="100%" height="320"
  style="border:0;max-width:680px"
  loading="lazy"
  title="STAT+: Eyepoint study results for vision treatment disappoint, but company still sees promise"></iframe>

STAT+: Eyepoint study results for vision treatment disappoint, but company still sees promise

How 1 sources are covering this

STAT+: Eyepoint study results for vision treatment disappoint, but company still sees promise

More from Health

STAT+: Sanofi to lay off 229 workers in Mass., a year after $9.1B Blueprint Medicines acquisition

STAT+: The IRS is probing UnitedHealth, and a private equity slowdown

STAT+: Akeso and Summit’s lung cancer drug shows worsening tumor-progression benefit

STAT+: Pharmalittle: We’re reading about an AstraZeneca setback, falling U.S. drug prices, and more

Reader

Trust & legal

Across the network

How 1 sources are covering this

STAT+: Eyepoint study results for vision treatment disappoint, but company still sees promise

More from Health

STAT+: Sanofi to lay off 229 workers in Mass., a year after $9.1B Blueprint Medicines acquisition

STAT+: The IRS is probing UnitedHealth, and a private equity slowdown

STAT+: Akeso and Summit&#8217;s lung cancer drug shows worsening tumor-progression benefit

STAT+: Pharmalittle: We&#8217;re reading about an AstraZeneca setback, falling U.S. drug prices, and more

Reader

Trust & legal

Across the network

STAT+: Akeso and Summit’s lung cancer drug shows worsening tumor-progression benefit

STAT+: Pharmalittle: We’re reading about an AstraZeneca setback, falling U.S. drug prices, and more